RxDoctor Payments Data

Daniel Kim, MD

Gastroenterology · Mission Viejo, CANPI 1548648868

Payments from drug & device makers

$8,632in general payments, 2019–2025

Across 387 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$870
  • Takeda Pharmaceuticals U.S.A., Inc.$760
  • Sanofi$440
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$382
  • Aimmune Therapeutics, Inc.$358
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$8,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,632 in reported general payments places this provider in the 70th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$112,646
Medicare patients
359
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide22$18,254
TrulancePlecanatide15$13,617
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C43$5,714
ClenpiqSod Picosulf/Mag Ox/Citric Ac27$4,712
SutabSod Sulf/Pot Chloride/Mag Sulf28$4,526
Omeprazole222$3,142
Sucralfate21$1,588
Dicyclomine Hcl52$1,401
Colestipol Hcl27$1,316
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg69$1,269
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$809
Pantoprazole Sodium53$797
Famotidine44$678
Ondansetron OdtOndansetron27$472
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine18$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$382$19,33258 claims
AbbVieLinzess$2,776$18,25422 claims
Ferring Pharmaceuticals Inc.Clenpiq$57$4,71227 claims
Braintree Laboratories, Inc.Sutab$136$4,52628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →